Core Viewpoint - Nvidia projects a significant growth in artificial intelligence (AI) spending, estimating a $3 trillion to $4 trillion infrastructure opportunity by 2030, driven by the top AI hyperscalers spending approximately $600 billion annually [2][3]. Group 1: Nvidia's Financial Projections - Nvidia generated $147 billion in data center revenue over the past four quarters, with expectations to exceed $182 billion for fiscal 2026, capturing a substantial share of AI hyperscaler spending [3]. - If Nvidia maintains or increases its share of AI spending, it could approach $1 trillion in revenue by 2030, a milestone not yet achieved by any company [4][9]. - Achieving $1 trillion in revenue would require Nvidia to maintain a compound annual growth rate (CAGR) of 39%, a challenging target for any company [9]. Group 2: Competitive Landscape - Retail giants Amazon and Walmart currently lead in revenue generation, with Amazon projected to reach the $1 trillion milestone in just over three years and Walmart in seven years, although Nvidia is growing at a faster rate [6][8]. - Nvidia reported a 56% revenue growth in its fiscal 2026 second quarter, despite challenges such as GPU sales restrictions to China [9]. Group 3: Market Dynamics and Future Outlook - The sustainability of Nvidia's growth rate hinges on substantial investments from AI hyperscalers and the overall expansion of AI demand [10]. - The future of AI technology deployment remains uncertain, with the most likely outcome being a scenario between Nvidia's optimistic projections and the current industry state, suggesting continued success for Nvidia [11].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Fortinet, Inc. and its officers or directors following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On August 6, 2025, Fortinet reported disappointing second quarter 2025 financial results, leading to confusion among investors regarding the company's performance [3]. - The company indicated that 40% to 50% of its accelerated firewall refresh, estimated at a $450 million opportunity, was completed, yet product revenue growth and billings did not meet expectations [3]. - Following the announcement, Fortinet's stock price fell by $21.28 per share, or 22.03%, closing at $75.30 per share on August 7, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Fortinet investors, suggesting potential securities fraud or other unlawful practices by the company and its leadership [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Bumble Inc. and its officers or directors, following a significant drop in the company's paying users and a subsequent decline in stock price [1][3][4]. Group 1: Company Performance - Bumble reported a 8.7% decrease in total paying users, dropping to 3.8 million in Q2 2025, compared to 4 million in Q1 2025 and 4.2 million in Q4 2024 [3]. - The company has introduced new AI-powered features aimed at enhancing trust and safety, but analysts suggest these measures may negatively impact user and payer growth in the short term due to stricter verification processes [3]. Group 2: Market Reaction - Following the release of its Q2 results, Bumble's stock price fell by $1.22, or 15.94%, closing at $6.43 per share on August 7, 2025 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and failed to account for rising customer acquisition costs, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of James Hardie Industries plc regarding potential securities fraud or unlawful business practices by the company and its officers [1] - James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [3] - Following the announcement of its financial results, James Hardie's ADR price fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [3] Company Overview - James Hardie Industries plc is facing scrutiny from investors and legal investigations related to possible securities fraud [1] - The company has experienced significant financial challenges, as indicated by the substantial decline in profit and negative earnings projections [3] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud [4]

Core Viewpoint - Zai Lab Limited is under investigation for potential securities fraud following the release of disappointing final results from a Phase 3 clinical trial for its drug bemarituzumab, leading to a significant drop in its stock price [1][3]. Group 1: Company Overview - Zai Lab Limited is a biopharmaceutical company listed on NASDAQ under the ticker ZLAB [1]. - The company is currently facing claims of securities fraud or unlawful business practices, prompting an investigation by Pomerantz LLP [1]. Group 2: Clinical Trial Results - On September 3, 2025, Zai Lab announced the completion of the final analysis of the Phase 3 FORTITUDE-101 trial for bemarituzumab in combination with chemotherapy for first-line gastric cancer [3]. - The interim analysis had shown a significant improvement in overall survival compared to chemotherapy alone, but the final analysis indicated that this survival advantage had diminished [3]. - Zai Lab plans to await results from the FORTITUDE-102 trial before proceeding with regulatory filing, with data readout expected by the end of 2025 or the first half of 2026 [3]. Group 3: Market Reaction - Following the announcement of the final trial results, Zai Lab's American Depositary Receipt (ADR) price fell by $2.04, or 6.12%, closing at $31.30 per ADR on September 3, 2025 [3].

Core Viewpoint - A class action lawsuit has been filed against Tronox Holdings Plc for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Tronox and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 3, 2025, to request to be appointed as Lead Plaintiff if they purchased Tronox securities during the Class Period [2]. Group 2: Financial Performance - On July 30, 2025, Tronox reported a significant reduction in sales of its TiO2 products, attributing the decline to a softer coatings season and heightened competition [4]. - Following the announcement, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60% [4]. - As a result of the negative news, Tronox's stock price fell by $1.95 per share, or 37.94%, closing at $3.19 per share on July 31, 2025 [5].

Core Viewpoint - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding the company's financial health and ability to manage macroeconomic challenges during the specified class period from January 30, 2025, to July 23, 2025 [1][4]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which led to a stock price drop of over 3% [5]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline, missing estimates by $130 million [6]. Group 2: Dividend and Market Conditions - Following disappointing financial results, Dow announced a dividend cut from $0.70 to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment [6]. - The CEO attributed the poor performance to a prolonged earnings downturn in the industry, exacerbated by trade and tariff uncertainties, and noted signs of oversupply from new market entrants [6]. Group 3: Legal Process and Representation - Investors who purchased Dow securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [7]. - Robbins Geller Rudman & Dowd LLP is recognized as a leading law firm in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. and certain officers for alleged violations of federal securities laws during the Class Period from January 30, 2025, to July 23, 2025, seeking damages for affected investors [1]. Company Overview - Dow is an American materials science company that operates in various industries, including packaging, infrastructure, mobility, and consumer applications, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings [4]. Financial Performance and Market Reaction - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00 per share due to ongoing weakness in key markets and pressure on the dividend, resulting in a 3.21% drop in stock price to $26.87 [6]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion reflecting a 7.3% year-over-year decline, missing estimates by $130 million [7]. - Following the disappointing financial results, Dow announced a dividend cut from $0.70 to $0.35 per share, leading to a 17.45% decline in stock price to $25.07 on July 24, 2025 [8]. Management Statements and Allegations - Dow's CEO, Jim Fitterling, previously emphasized the importance of the dividend to investors, claiming that over 65% of shareholders rely on it, while asserting that the company was well-positioned to handle macroeconomic challenges [5]. - The lawsuit alleges that Dow's management made materially false and misleading statements regarding the company's ability to navigate economic headwinds and maintain financial flexibility, which were overstated [5].

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. (“Skillz” or the “Company”) (NYSE: SKLZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Skillz and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 2, 2025 ...